Combinatorial therapy for Deafness: A therapeutic mix encompassing Exemestane, Cholecalciferol, Ajoene and DIM (ECAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via upregulation of its target genes, 24/August/2018, 10.45 pm

Serelaxin (SLX)-based therapy for cardiac hypertrophy and fibrosis: Serelaxin (SLX), a recombinant relaxin-2, decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 24/August/2018, 2.52 pm
August 24, 2018
The pregnancy hormone Relaxin relieves you of acute and chronic pain (No kidding): Relaxin-based activation of the PD-1 pathway for Pain therapy: Relaxin, a protein hormone that facilitates labor and relaxes the uterine musculature,  increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 24/August/2018, 11.08 pm
August 24, 2018
Show all

What we say:

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for Deafness: A therapeutic mix encompassing Exemestane, Cholecalciferol, Ajoene and DIM (ECAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via upregulation of its target genes

[easy_payment currency=”USD”]


From Significance of the study to Public health relevance:

Given that: (1) more than one-seventh of the global population suffers from hearing impairment;  (2) the majority of hearing impairment occurs in  low and middle-income countries, for instance, 3 in 1000 from developed countries, while 6 in 1000 from developing countries suffer from hearing impairment; (3) damage to the auditory hair cells (HCs) is the principal reason for hearing loss;  (4) only in 50% cases hearing impairment can be cured; and (5) the global annual economic cost spent for unaddressed hearing loss is estimated to be in the range of $750–790 billion, there is an urgent need to find: (i) a way to promote regeneration, growth, and proliferation of auditory hair cells  in mammalian cochlea; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, hearing impairment.


From research findings to Therapeutic opportunity: 

This study provides, for the first time, mechanistic insights into how a pharmaceutical mixture encompassing Exemestane, Cholecalciferol, Ajoene and DIM (ECAD)  may aid in the treatment of hearing impairment.

ECAD, by increasing the expression of its target genes, it may increase the expression of longevity-promoting gene ATG5 (Autophagy-related protein 5). Thereby, it may: (1) prevent degeneration of adult hair cells; (2) prevent aggregation of polyubiquitinated proteins and p62/SQSTM1 in inclusion bodies; (3) promote maintenance of hair cells morphology and hearing acuity; and (4) prevent hearing loss. Thus, pharmacological mixture encompassing “Exemestane, Cholecalciferol, Ajoene and DIM (ECAD) or their analogseither alone or in combination with other drugs, may be used to treat deafness (Fig.1).

Figure 1 Mechanistic insights into how a therapeutic mix encompassing Exemestane, Cholecalciferol, Ajoene and DIM (ECAD) aids in improving hearing impairment. ECAD prevents aggregation of proteins, promotes regeneration of adult hair cells and inhibits hearing impairment via up-regulation of its target gene ATG5

Figure 2 Exemestane prevents hearing loss through induction of ATG5

 

 

[easy_payment currency=”USD”]

 

 

 

 

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does a therapeutic mix encompassing Exemestane, Cholecalciferol, Ajoene and DIM (ECAD)  increase the expression of ATG5?

Amount: $500#

For payment and purchase details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Combinatorial therapy for Deafness: A therapeutic mix encompassing Exemestane, Cholecalciferol, Ajoene and DIM (ECAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via upregulation of its target genes, 24/August/2018, 10.45 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at admin@genomediscovery.org

Comments are closed.